Pharmarise Holdings Corporation (TYO:2796)
Japan · Delayed Price · Currency is JPY 489.00
-2.00 (-0.41%)
Jul 31, 2026, 3:30 PM JST
Pharmarise Holdings Cash Flow Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Net Income | 114 | 8 | 143 | 1,049 | 1,322 |
Depreciation & Amortization | 1,605 | 1,493 | 1,170 | 1,224 | 1,308 |
Loss (Gain) From Sale of Assets | -10 | 256 | 297 | 396 | 216 |
Asset Writedown & Restructuring Costs | 48 | - | - | - | - |
Loss (Gain) From Sale of Investments | - | -3 | -19 | - | - |
Other Operating Activities | 219 | -426 | -990 | -745 | -869 |
Change in Accounts Receivable | 186 | 392 | 1,437 | 482 | -1,319 |
Change in Inventory | 1,464 | -1,091 | -26 | 68 | 286 |
Change in Accounts Payable | -372 | 910 | 137 | 13 | -500 |
Change in Other Net Operating Assets | 24 | -228 | 565 | 33 | 269 |
Operating Cash Flow | 3,278 | 1,311 | 2,714 | 2,520 | 713 |
Operating Cash Flow Growth | 150.04% | -51.70% | 7.70% | 253.44% | -63.34% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Capital Expenditures | -696 | -637 | -472 | -380 | -379 |
Sale of Property, Plant & Equipment | 20 | 3 | 16 | 32 | 2 |
Cash Acquisitions | -1,289 | -301 | -2,401 | -180 | - |
Divestitures | 9 | - | - | - | - |
Sale (Purchase) of Intangibles | -25 | -65 | -147 | -162 | -87 |
Investment in Securities | 20 | 49 | 43 | - | - |
Other Investing Activities | -11 | -3,510 | -47 | -13 | 171 |
Investing Cash Flow | -1,975 | -4,462 | -3,120 | -703 | -292 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Long-Term Debt Issued | 3,000 | 5,100 | 6,100 | 1,700 | 2,000 |
Long-Term Debt Repaid | -2,924 | -3,716 | -2,586 | -2,419 | -2,636 |
Total Debt Repaid | -2,924 | -3,716 | -2,586 | -2,419 | -2,636 |
Net Debt Issued (Repaid) | 76 | 1,384 | 3,514 | -719 | -636 |
Repurchase of Common Stock | - | - | -340 | - | -2 |
Common Dividends Paid | -158 | -224 | -127 | -131 | -131 |
Other Financing Activities | -99 | -221 | -276 | -222 | -265 |
Financing Cash Flow | -181 | 939 | 2,771 | -1,072 | -1,034 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Miscellaneous Cash Flow Adjustments | -1 | 3 | 1 | -2 | - |
Net Cash Flow | 1,121 | -2,209 | 2,366 | 743 | -613 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Free Cash Flow | 2,582 | 674 | 2,242 | 2,140 | 334 |
Free Cash Flow Growth | 283.09% | -69.94% | 4.77% | 540.72% | -76.76% |
Free Cash Flow Margin | 3.71% | 1.06% | 4.12% | 4.11% | 0.65% |
Free Cash Flow Per Share | 216.61 | 59.53 | 213.04 | 171.61 | 26.94 |
Levered Free Cash Flow | 2,368 | 457.13 | 2,824 | 1,975 | 221 |
Unlevered Free Cash Flow | 2,546 | 568.38 | 2,866 | 2,009 | 261.63 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Cash Interest Paid | 293 | 191 | 71 | 55 | 66 |
Cash Income Tax Paid | 409 | 436 | 726 | 836 | 870 |
Change in Working Capital | 1,302 | -17 | 2,113 | 596 | -1,264 |